Autologous peripheral blood stem cell transplantation using MEAM regimen with HAART for refractory and relapsed HIV associated lymphoma: multicentered phase2 clinical trial
Phase 2
- Conditions
- Refractory and relapsed HIV associated lymphoma
- Registration Number
- JPRN-UMIN000003159
- Lead Sponsor
- Research fund of Ministry Health, Labour and Welfare for a counter measure against AIDS, Okada group and Tanabe group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
Not provided
Exclusion Criteria
heart failure, live dysfunction, renal dysfunction uncontrollable opportunistic infection uncontrollable diabetes uncontrollable HIV infection by HAART
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Engraftment and survival at day 100 post transplantation
- Secondary Outcome Measures
Name Time Method 1year and 2year overall survival progression free survival event free survival therapy related toxicity remission rate number of CD4 positive cell and quantity of HIV-RNA